- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 11/12 - Mucolytics
Patent holdings for IPC class A61P 11/12
Total number of patents in this class: 235
10-year publication summary
|
10
|
22
|
15
|
17
|
22
|
13
|
12
|
12
|
19
|
5
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| The Regents of the University of California | 20587 |
9 |
| Enterprise Therapeutics Limited | 20 |
9 |
| Translate bio, Inc. | 413 |
8 |
| Vertex Pharmaceuticals Incorporated | 1595 |
6 |
| Parion Sciences, Inc. | 57 |
5 |
| University College Dublin, National University of Ireland, Dublin | 357 |
5 |
| Boehringer Ingelheim International GmbH | 4496 |
4 |
| Universite de Poitiers | 192 |
4 |
| The University of North Carolina at Chapel Hill | 2078 |
4 |
| Know bio, LLC | 81 |
4 |
| Centre National de La Recherche Scientifique | 10895 |
3 |
| The Board of Trustees of the Leland Stanford Junior University | 6605 |
3 |
| AbbVie S.á.r.l. | 27 |
3 |
| Algipharma AS | 44 |
3 |
| Galapagos NV | 273 |
3 |
| Inserm (institut National de La Sante et de La Recherche Medicale) | 3331 |
3 |
| University College Dublin | 6 |
3 |
| Czap Research and Development, LLC | 15 |
3 |
| Frimline Private Limited | 15 |
3 |
| Mucpharm Pty Ltd | 13 |
3 |
| Other owners | 147 |